{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:21:46Z","timestamp":1792030906067,"version":"4.4.0"},"reference-count":94,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JASN"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:p>The introduction of corticosteroids and later, cyclophosphamide dramatically improved survival in patients with proliferative lupus nephritis, and combined administration of these agents became the standard-of-care treatment for this disease. However, treatment failures were still common and the rate of progression to ESRD remained unacceptably high. Additionally, treatment was associated with significant morbidity. Therefore, as patient survival improved, the goals for advancing lupus nephritis treatment shifted to identifying therapies that could improve long-term renal outcomes and minimize treatment-related toxicity. Unfortunately, progress has been slow and the current approaches to the management of lupus nephritis continue to rely on high-dose corticosteroids plus a broad-spectrum immunosuppressive agent. Over the past decade, an improved understanding of lupus nephritis pathogenesis fueled several clinical trials of novel drugs, but none have been found to be superior to the combination of a cytotoxic agent and corticosteroids. Despite these trial failures, efforts to translate mechanistic advances into new treatment approaches continue. In this review, we discuss current therapeutic strategies for lupus nephritis, briefly review recent advances in understanding the pathogenesis of this disease, and describe emerging approaches developed on the basis of these advances that promise to improve upon the standard-of-care lupus nephritis treatments.<\/jats:p>","DOI":"10.1681\/asn.2016040415","type":"journal-article","created":{"date-parts":[[2016,6,9]],"date-time":"2016-06-09T22:21:46Z","timestamp":1465510906000},"page":"2929-2939","source":"Crossref","is-referenced-by-count":90,"title":["Current and Emerging Therapies for Lupus Nephritis"],"prefix":"10.1681","volume":"27","author":[{"given":"Samir V.","family":"Parikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad H.","family":"Rovin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,6,9]]},"reference":[{"key":"B2-20231016","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1681\/ASN.V102413","article-title":"Lupus nephritis.","volume":"10","author":"Cameron","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"B4-20231016","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/art.30293","article-title":"Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006.","volume":"63","author":"Costenbader","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B5-20231016","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198603063141004","article-title":"Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs.","volume":"314","author":"Austin","year":"1986","journal-title":"N Engl J Med"},{"key":"B6-20231016","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1146\/annurev.me.31.020180.002335","article-title":"The natural history and response to therapy of lupus nephritis.","volume":"31","author":"Ginzler","year":"1980","journal-title":"Annu Rev Med"},{"key":"B7-20231016","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.","volume":"20","author":"Appel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B8-20231016","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/art.38260","article-title":"Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study.","volume":"66","author":"Furie","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B9-20231016","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"B10-20231016","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B11-20231016","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.md.0000091181.93122.55","article-title":"Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.","volume":"82","author":"Cervera","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"B12-20231016","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/rheumatology\/kep012","article-title":"Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort.","volume":"48","author":"Danila","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"B13-20231016","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013010026","article-title":"The pathogenesis of lupus nephritis.","volume":"24","author":"Lech","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B14-20231016","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide.","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B15-20231016","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.38790","article-title":"Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study.","volume":"66","author":"Group","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B17-20231016","first-page":"100","article-title":"Malignancies in Wegener\u2019s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients.","volume":"35","author":"Faurschou","year":"2008","journal-title":"J Rheumatol"},{"key":"B18-20231016","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","article-title":"Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis.","volume":"343","author":"Chan","year":"2000","journal-title":"N Engl J Med"},{"key":"B19-20231016","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.","volume":"353","author":"Ginzler","year":"2005","journal-title":"N Engl J Med"},{"key":"B20-20231016","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.","volume":"365","author":"Dooley","year":"2011","journal-title":"N Engl J Med"},{"key":"B21-20231016","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2215\/CJN.03290412","article-title":"Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice?","volume":"8","author":"Rovin","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"B24-20231016","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMoa031855","article-title":"Sequential therapies for proliferative lupus nephritis.","volume":"350","author":"Contreras","year":"2004","journal-title":"N Engl J Med"},{"key":"B25-20231016","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1172\/JCI200318384","article-title":"Azathioprine: old drug, new actions.","volume":"111","author":"Maltzman","year":"2003","journal-title":"J Clin Invest"},{"key":"B26-20231016","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1136\/ard.2010.131995","article-title":"Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B27-20231016","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","article-title":"Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.","volume":"71","author":"Bertsias","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B28-20231016","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.4049\/jimmunol.0801607","article-title":"Type I interferon (IFN alpha) acts directly on human memory CD4+ T cells altering their response to antigen.","volume":"183","author":"Gallagher","year":"2009","journal-title":"J Immunol"},{"key":"B29-20231016","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1074-7613(03)00208-5","article-title":"Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6.","volume":"19","author":"Jego","year":"2003","journal-title":"Immunity"},{"key":"B30-20231016","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1182\/blood-2008-11-188458","article-title":"Reciprocal responsiveness to interleukin-12 and interferon-alpha specifies human CD8+ effector versus central memory T-cell fates.","volume":"113","author":"Ramos","year":"2009","journal-title":"Blood"},{"key":"B31-20231016","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.smim.2011.01.009","article-title":"The type I interferon system in the development of lupus.","volume":"23","author":"R\u00f6nnblom","year":"2011","journal-title":"Semin Immunol"},{"key":"B32-20231016","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/art.23186","article-title":"Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18.","volume":"58","author":"Tucci","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B33-20231016","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.4049\/jimmunol.1001983","article-title":"In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis.","volume":"186","author":"Chang","year":"2011","journal-title":"J Immunol"},{"key":"B34-20231016","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/acr.20441","article-title":"Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring.","volume":"63","author":"Hsieh","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B35-20231016","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1681\/ASN.2010060647","article-title":"Complement factor H deficiency accelerates development of lupus nephritis.","volume":"22","author":"Bao","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B36-20231016","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.molimm.2011.09.015","article-title":"The dual role of complement in the progression of renal disease in NZB\/W F(1) mice and alternative pathway inhibition.","volume":"49","author":"Sekine","year":"2011","journal-title":"Mol Immunol"},{"key":"B37-20231016","doi-asserted-by":"crossref","first-page":"786","DOI":"10.4049\/jimmunol.164.2.786","article-title":"Modulation of renal disease in MRL\/lpr mice genetically deficient in the alternative complement pathway factor B.","volume":"164","author":"Watanabe","year":"2000","journal-title":"J Immunol"},{"key":"B38-20231016","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1681\/ASN.2005040373","article-title":"C5a receptor deficiency attenuates T cell function and renal disease in MRLlpr mice.","volume":"16","author":"Wenderfer","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B39-20231016","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1002\/1529-0131(200109)44:9<2097::AID-ART360>3.0.CO;2-6","article-title":"Predominance of Th1 immune response in diffuse proliferative lupus nephritis.","volume":"44","author":"Masutani","year":"2001","journal-title":"Arthritis Rheum"},{"key":"B40-20231016","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2249.2008.03758.x","article-title":"Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis.","volume":"154","author":"Tucci","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"B41-20231016","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.semnephrol.2006.09.007","article-title":"T cells and B cells in lupus nephritis.","volume":"27","author":"Foster","year":"2007","journal-title":"Semin Nephrol"},{"key":"B42-20231016","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/01.bor.0000132646.55056.e0","article-title":"T lymphocytes in systemic lupus erythematosus: an update.","volume":"16","author":"Kyttaris","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"B43-20231016","doi-asserted-by":"crossref","first-page":"8761","DOI":"10.4049\/jimmunol.181.12.8761","article-title":"Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys.","volume":"181","author":"Crisp\u00edn","year":"2008","journal-title":"J Immunol"},{"key":"B44-20231016","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"B45-20231016","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.4049\/jimmunol.0901163","article-title":"Cutting edge: Regulatory T cells directly suppress B cells in systemic lupus erythematosus.","volume":"183","author":"Iikuni","year":"2009","journal-title":"J Immunol"},{"key":"B46-20231016","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00403-008-0891-9","article-title":"CD4(+)CD25 (+) regulatory T cells in human lupus erythematosus.","volume":"301","author":"Kuhn","year":"2009","journal-title":"Arch Dermatol Res"},{"key":"B47-20231016","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.coi.2010.09.010","article-title":"Targeting BAFF in autoimmunity.","volume":"22","author":"Davidson","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"B48-20231016","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/art.23678","article-title":"Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.","volume":"58","author":"Petri","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B49-20231016","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1177\/0961203313496302","article-title":"Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus.","volume":"22","author":"Vincent","year":"2013","journal-title":"Lupus"},{"key":"B51-20231016","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.4049\/jimmunol.178.3.1960","article-title":"Increased levels of NF-ATc2 differentially regulate CD154 and IL-2 genes in T cells from patients with systemic lupus erythematosus.","volume":"178","author":"Kyttaris","year":"2007","journal-title":"J Immunol"},{"key":"B52-20231016","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system.","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol Rev"},{"key":"B53-20231016","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev.immunol.14.1.233","article-title":"CD28\/B7 system of T cell costimulation.","volume":"14","author":"Lenschow","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"B54-20231016","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.4049\/jimmunol.166.5.2913","article-title":"Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide.","volume":"166","author":"Daikh","year":"2001","journal-title":"J Immunol"},{"key":"B55-20231016","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4049\/jimmunol.171.1.489","article-title":"Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB\/W F1 mice by a mechanism downstream of renal immune complex deposition.","volume":"171","author":"Schiffer","year":"2003","journal-title":"J Immunol"},{"key":"B56-20231016","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B57-20231016","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1002\/art.22044","article-title":"Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.","volume":"54","author":"Feng","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B58-20231016","doi-asserted-by":"crossref","first-page":"e000112","DOI":"10.1136\/lupus-2015-000112","article-title":"Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders.","volume":"2","author":"Parikh","year":"2015","journal-title":"Lupus Sci Med"},{"key":"B59-20231016","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.semnephrol.2015.08.006","article-title":"The Complement System in Lupus Nephritis.","volume":"35","author":"Birmingham","year":"2015","journal-title":"Semin Nephrol"},{"key":"B60-20231016","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0162-3109(99)00018-1","article-title":"Systemic lupus erythematosus and complement deficiency: clues to a novel role for the classical complement pathway in the maintenance of immune tolerance.","volume":"42","author":"Navratil","year":"1999","journal-title":"Immunopharmacology"},{"issue":"Suppl 3","key":"B61-20231016","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.1186\/ar586","article-title":"Complement and systemic lupus erythematosus.","volume":"4","author":"Walport","year":"2002","journal-title":"Arthritis Res"},{"key":"B62-20231016","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1172\/JCI112217","article-title":"Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization.","volume":"76","author":"Schifferli","year":"1985","journal-title":"J Clin Invest"},{"key":"B63-20231016","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1177\/0961203310371154","article-title":"The complex nature of serum C3 and C4 as biomarkers of lupus renal flare.","volume":"19","author":"Birmingham","year":"2010","journal-title":"Lupus"},{"key":"B64-20231016","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.4049\/jimmunol.180.2.1231","article-title":"Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL\/lpr mice.","volume":"180","author":"Atkinson","year":"2008","journal-title":"J Immunol"},{"key":"B65-20231016","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/art.30222","article-title":"The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL\/lpr mice.","volume":"63","author":"Sekine","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B66-20231016","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B67-20231016","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/0961203312465781","article-title":"Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.","volume":"22","author":"Dooley","year":"2013","journal-title":"Lupus"},{"key":"B68-20231016","article-title":"The impact of tabalumab on the kidney in systemic lupus erythematosus: results from 2 phase 3 randomized, clinical trials","author":"Rovin","journal-title":"Lupus"},{"key":"B69-20231016","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1002\/art.30466","article-title":"B cell biomarkers of rituximab responses in systemic lupus erythematosus.","volume":"63","author":"Vital","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B70-20231016","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/01.tp.0000282786.58754.2b","article-title":"Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection.","volume":"84","author":"Steinmetz","year":"2007","journal-title":"Transplantation"},{"key":"B71-20231016","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"key":"B72-20231016","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"key":"B73-20231016","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/annrheumdis-2012-202071","article-title":"Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren\u2019s syndrome: data from a placebo-controlled clinical trial.","volume":"72","author":"Pollard","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B74-20231016","doi-asserted-by":"crossref","first-page":"6405","DOI":"10.4049\/jimmunol.176.11.6405","article-title":"Space, selection, and surveillance: setting boundaries with BLyS.","volume":"176","author":"Miller","year":"2006","journal-title":"J Immunol"},{"key":"B75-20231016","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.immuni.2004.05.010","article-title":"Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches.","volume":"20","author":"Thien","year":"2004","journal-title":"Immunity"},{"key":"B76-20231016","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1084\/jem.20052033","article-title":"A checkpoint for autoreactivity in human IgM+ memory B cell development.","volume":"203","author":"Tsuiji","year":"2006","journal-title":"J Exp Med"},{"key":"B77-20231016","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/ard.2007.079418","article-title":"B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.","volume":"67","author":"Cambridge","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B78-20231016","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1136\/annrheumdis-2013-203455","article-title":"Autoantibodies from long-lived \u2018memory\u2019 plasma cells of NZB\/W mice drive immune complex nephritis.","volume":"72","author":"Cheng","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B79-20231016","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1681\/ASN.2010050515","article-title":"Local renal autoantibody production in lupus nephritis.","volume":"22","author":"Espeli","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B80-20231016","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation.","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl 4","key":"B81-20231016","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1186\/ar1009","article-title":"B cell abnormalities in systemic lupus erythematosus.","volume":"5","author":"Grammer","year":"2003","journal-title":"Arthritis Res Ther"},{"key":"B82-20231016","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1159\/000334955","article-title":"The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB\/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture.","volume":"120","author":"Hainz","year":"2012","journal-title":"Nephron, Exp Nephrol"},{"key":"B83-20231016","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.intimp.2011.11.019","article-title":"Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE.","volume":"12","author":"Seavey","year":"2012","journal-title":"Int Immunopharmacol"},{"key":"B84-20231016","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7754\/Clin.Lab.2012.120215","article-title":"Bortezomib modulates regulatory T cell subpopulations in the process of acute graft-versus-host disease.","volume":"59","author":"Weng","year":"2013","journal-title":"Clin Lab"},{"key":"B85-20231016","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B86-20231016","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"B87-20231016","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1093\/ndt\/gfp336","article-title":"Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.","volume":"24","author":"Pepper","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"B88-20231016","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B89-20231016","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/art.10856","article-title":"A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis.","volume":"48","author":"Boumpas","year":"2003","journal-title":"Arthritis Rheum"},{"key":"B90-20231016","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13075-015-0757-4","article-title":"CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study.","volume":"17","author":"Shock","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B91-20231016","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial.","volume":"162","author":"Liu","year":"2015","journal-title":"Ann Intern Med"},{"key":"B92-20231016","doi-asserted-by":"crossref","first-page":"e31465","DOI":"10.1371\/journal.pone.0031465","article-title":"Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of na\u00efve T cells into cytokine-producing mature T cells.","volume":"7","author":"Tsuda","year":"2012","journal-title":"PLoS One"},{"key":"B93-20231016","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMcibr0806881","article-title":"Proteinuria and immunity--an overstated relationship?","volume":"359","author":"Mathieson","year":"2008","journal-title":"N Engl J Med"},{"key":"B94-20231016","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1177\/0961203310371155","article-title":"Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study.","volume":"19","author":"Zavada","year":"2010","journal-title":"Lupus"},{"key":"B95-20231016","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2014-206456","article-title":"Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.","volume":"75","author":"Mok","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B97-20231016","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/art.1780250732","article-title":"Immunopathology of the membrane attack complex in systemic lupus erythematosus nephritis.","volume":"25","author":"Biesecker","year":"1982","journal-title":"Arthritis Rheum"},{"key":"B98-20231016","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.clim.2013.02.014","article-title":"Targeting the complement system in systemic lupus erythematosus and other diseases.","volume":"148","author":"Barilla-Labarca","year":"2013","journal-title":"Clin Immunol"},{"key":"B100-20231016","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2013020143","article-title":"C5a receptor (CD88) blockade protects against MPO-ANCA GN.","volume":"25","author":"Xiao","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B103-20231016","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1002\/eji.200526327","article-title":"C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist.","volume":"35","author":"Bao","year":"2005","journal-title":"Eur J Immunol"},{"key":"B104-20231016","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12865-015-0070-7","article-title":"IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment.","volume":"16","author":"Zickert","year":"2015","journal-title":"BMC Immunol"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201610000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:27:59Z","timestamp":1786130879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201610000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,9]]},"references-count":94,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2016040415","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726413787.793519601","asserted-by":"object"}]},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,9]]}}}